Amgen Backs Tizona Therapeutics In $43M Funding

Thousand Oaks-based Amgen has made another investment this morning in immunology startup Tizona Therapeutics, via its venture capital arm, Amgen Ventures. According to Tizona Therapeutics, it completed a $43M Series B financing round, which was led by Abingworth and Canaan Partners. Series A investors--including Amgen Ventures--also participated, with investments from MPM Capital, Astellas Venture Management and InterWest Partners. Lightstone Ventures also participated in the funding. Tizona is based in South San Francisco, and is developing treatments for cancer and autoimmune diseases. More information »